<DOC>
	<DOC>NCT00522067</DOC>
	<brief_summary>This phase II, open label, is designed as a seasonal study to support annual strain update evaluating the safety, clinical tolerability and immunogenicity of the 2007-2008 formulation of Novartis Vaccines' adjuvanted, subunit influenza vaccine in adults with underlying chronic diseases</brief_summary>
	<brief_title>Support Annual Strain Update, Safety and Immunogenicity of an Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008, When Administered to Subjects 18-64 Years Affected by Chronic Diseases.</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 to 64 years of age adult volunteers, mentally competent, willing and able to give written informed consent prior to study entry, suffering from at least one of these chronic diseases: hypertension, heart disease, chronic obstructive pulmonary disease (COPD) or asthma, hepatic or renal insufficiency, arteriosclerotic disease or insulin dependent diabetes mellitus Hypersensitivity to ovalbumin, chicken protein, chicken feathers, influenza viral protein, kanamycin and neomycin sulphate or any other component of the vaccine; History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine; Known or suspected impairment/ alteration of immune function; Having received within the past 12 months more than one injection of influenza vaccine Any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>adjuvanted influenza vaccine</keyword>
	<keyword>subunit influenza vaccine</keyword>
	<keyword>surface antigen</keyword>
</DOC>